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Abstract
Purpose 18F-FDG PET/CT should be performed before a di-
agnostic biopsy site is chosen in patients with a high clinical
suspicion of aggressive, advanced tumour. The aim of this
study was to evaluate the safety and efficacy of 18F-FDG
PET/CT in guiding biopsy of bone metastases in patients with
advanced lung cancer.
Methods PET/CT-guided percutaneous core biopsies were
performed in 51 consecutive patients with suspected lung can-
cer and 18F-FDG-avid bone lesions after whole-body 18F-
FDG PET/CT scans. Generally, one tissue sample was obtain-
ed from each patient. The final diagnoses were established on
the basis of the histology results. The histopathological and
molecular testing results were systematically evaluated.
Results A total of 53 samples were obtained for histological
examination or molecular testing as a second biopsy was re-
quired in two patients in whom the pathological diagnosis was
unclear following the first biopsy. The pathological diagnosis
and lung cancer classification were confirmed in 48 patients.
The epidermal growth factor receptor mutation status was de-
termined in 23 biopsies, and the mutation rate was 30.4 %
(7/23). The anaplastic lymphoma kinase mutation status was
determined in 19 biopsies, and the mutation rate was 31.6 %
(6/19). Two of the 51 biopsies were positive for non-
Hodgkin’s lymphoma and one was positive for metastatic re-
nal cell carcinoma. The first-time diagnostic success rate of
biopsy was 96.1 % (49/51) and the overall diagnostic success
rate and sensitivity were 100 %. All 51 patients were eventu-
ally confirmed as having stage IV disease. No serious compli-
cations were encountered and the average biopsy time was
30 min.
Conclusion PET/CT-guided percutaneous biopsy of 18F-
FDG-avid bone metastases is an effective and safe method
that yields a high diagnostic success rate in the evaluation of
hypermetabolic bone lesions in patients with suspected ad-
vanced lung cancer.
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Introduction
Lung cancer is the primary cause of cancer-related mortality
worldwide [1]. When the tumour is limited to the lung, with
minimal regional lymph node spread, the most effective ther-
apy is surgery. However, most patients present with locally
advanced or metastatic disease and are ineligible for surgical
resection. Besides surgical treatment, radiation and chemo-
therapy, molecularly targeted drugs have emerged as viable
therapeutic options in patients with advanced and therefore
inoperable cancer. Molecular targets include epidermal
growth factor receptor (EGFR), tyrosine kinase inhibitors
(TKIs; gefitinib and erlotinib) [2], and anaplastic lymphoma
kinase (ALK) TKIs (crizotinib) [3]. Improved pretherapeutic
staging, as part of a comprehensive approach to therapy, can
limit unnecessary surgical interventions and provide greater
benefit to patients.
18F-FDG PET/CT has been used to evaluate the extent of
disease in cancer patients and to provide more accurate stag-
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Network (NCCN) guidelines for non-small-cell lung cancer
(NSCLC), 18F-FDG PET can play an important role in the
evaluation and accurate staging of NSCLC. However, the
guidelines also advocate that each positive PET scan finding
for distant disease requires pathological or other radiological
confirmation, with biopsy preferred to other methods. Since
approximately 30 % to 65 % of patients with metastatic lung
carcinoma will develop bone metastases [5], bone biopsy can
aid in tumour staging of lung cancer patients with suspected
bone metastases.
Although the use of18F-FDG PET/CT-guided percutaneous
biopsy has been reported in several types of malignant tumour
[6, 7], its use for the biopsy of 18F-FDG-avid metastatic bone
lesions has not been reported in patients with advanced lung
cancer. The goal of the present study was to evaluate the safety
and efficacy of 18F-FDG PET/CT guided biopsy of 18F-FDG-
avid metastatic bone lesions in patients with advanced lung
cancer. The disease in the lung cancer patients was staged on
the basis of histopathological examination. In addition,
adequate tissue samples from bone biopsies allow more
beneficial molecular tests to be performed (i.e. determi-
nation of EGFR mutation status and ALK mutation sta-
tus), which may identify candidates for individualized
treatment and targeted therapy.
Materials and methods
Patients
This retrospective evaluation of collected data was approved
by the ethics committee of our institution. All patients gave
their written informed consent prior to the intervention.
Between January 2013 and September 2015, 18F-FDG PET/
CT-guided bone biopsies of metabolically active lesions were
performed in 51 consecutive patients (average age 59.7 years,
range 41 – 83 years; 35 men, 16 women) who had undergone
whole-body 18F-FDG PET/CT for suspected lung cancer. All
the patients were biopsied as inpatients and were kept under
observation for at least 2 h after the biopsy.
18F-FDG PET/CT
All patients were asked to fast for at least 4 h prior to under-
going 18F-FDG PET/CT. Prior to the scan, all patients re-
ceived an intravenous injection of 370 – 666 MBq
(10 – 18 mCi) of 18F-FDG. Data were acquired within
45 min of injection using an integrated PET/CT system
(Discovery STE; GE Medical Systems, Milwaukee, WI).
The procedure for data acquisition was as follows. CT scan-
ning was performed from the head to the pelvic floor and was
matched to the PET section thickness. A PET emission scan
was obtained that covered the identical transverse field of
view. The acquisition time was 3 min per table position.
PET imaging datasets were reconstructed iteratively by apply-
ing the CT data for attenuation correction, and coregistered
images were displayed on a workstation.
18F-FDG PET/CT-guided bone biopsy
After the whole-body 18F-FDG PET/CT scan the previous
day, a board-certified interventional radiologist and nuclear
medicine physician performed the bone biopsies in a PET/
CT suite dedicated to biopsy procedures. PET/CT-guided
bone biopsies were performed using a step-by-step technique.
In order to reduce radiation exposure to the medical staff dur-
ing the biopsy procedures, bone biopsies were scheduled on
separate days.
Patients were positioned in a prone or supine position de-
pending on factors such as target location, optimal needle
path, and shortest skin-to-target distance. Interventions were
performed under aseptic conditions after administration of lo-
cal anaesthetic with lidocaine.
The needle was introduced in a stepwise manner under
fused PET/CT and CT imaging guidance. The bone biopsy
needle, either a 16G (Magum, Bard, AZ) or an 11G (BMN-
B, SA Medical & Plastic Instruments Co., Ltd, Shanghai,
China), was chosen depending on the nature of the lesion
(i.e. whether it was an osteoblastic or osteolytic metastasis),
and its location and depth. One sample was obtained from
each patient, and histopathology and immunohistochemical
or molecular diagnosis were performed on each specimen.
18F-FDG PET/CT images in representative patients undergo-
ing bone biopsy are shown in Figs 1, 2, 3 and 4.
Follow-up of the primary lung lesion
All biopsy results were confirmed and a final diagnosis was
made in all patients. If the pathological diagnosis based on the
bone lesion was not metastatic lung cancer, the pathological
results from lung nodules were obtained.
Results
18F-FDG PET/CT-guided biopsies
The hypermetabolic bone lesions of interest were successfully
targeted and representative tissue samples of the metabolically
active sites were obtained in all 51 patients. The biopsy sites
are shown in Table 1. A total of 51 samples were obtained for
histological examination, and immunohistochemical and/or
molecular tests.
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Pathological diagnosis from bone biopsy samples
Of the 51 biopsies, 48 were positive for lung cancer (94.1 %;
Tables 1 and 2) and 3 were positive for other malignancies
(5.9 %; Tables 1 and 3). The 48 lung cancers included 36 ade-
nocarcinomas, 3 squamous carcinomas, 8 small-cell carcinomas,
and 1 sarcomatoid carcinoma.The three other malignancies in-
cluded one metastatic renal cell carcinoma (RCC) and two non-
Hodgkin’s lymphoma (NHL). The patient with RCC had
undergone tumour resection 3 years prior to this study. The re-
maining two patients with NHL had no history of malignancy.
They both underwent PET/CT-guided lung nodule biopsy, and
histology eventually confirmed the primary tumours as NHL.
Success rate of 18F-FDG PET/CT-guided bone biopsies
Although only one tissue sample was taken from each patient,
there was sufficient tissue to perform haematoxylin and eosin
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Fig. 1 A 58-year-old woman with suspected lung carcinoma and bone
metastasis. a, b, d 18F-FDG PET/CT imaging (a maximum intensity
projection image, b, d axial fusion images) shows uptake (SUVmax
4.6) in a lesion in the third lumbar vertebra on the right (a, b yellow
arrows) which is highly suspicious of metastasis, and uptake (SUVmax
11.3) in a lung nodule in the right lower lobe (a, d white arrows). c Axial
noncontrast CT image (using bone windows) shows the biopsy needle
positioned within the lesion (yellow arrow). e Axial CT image shows the
biopsy needle positioned within the lung nodule (white arrow).
Histological examination confirmed the bone lesion as metastatic
poorly differentiated adenocarcinoma and the lung nodule as primary
adenosquamous carcinoma, and exon 19 deletion mutation in EGFR
was detected in both samples
Fig. 2 A 61-year-old woman with suspected lung carcinoma with bone
metastasis. a–c 18F-FDG PET/CT imaging (a maximum intensity
projection image. b axial PET image. c axial PET/CT fusion image)
shows uptake (SUVmax 4.8) in a left femoral neck lesion (arrows)
highly suspicious of metastasis. d The CT image shows the biopsy
needle positioned within the left femoral neck lesion (arrow). e The
axial noncontrast CT image (using bone windows) shows osteolysis
within the corresponding hypermetabolic region (arrow). Histological
examination confirmed a bone metastasis from lung adenocarcinoma,
and exon 19 deletion mutation in EGFR was detected
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(H&E) staining, immunohistochemical tests, and molecular
tests. The first-time diagnostic success rate of 18F-FDG PET/
CT-guided bone biopsy was 96.1 % (49/51). The overall sen-
sitivity and the diagnostic success rate were 100 %.
Staging results in all 51 patients
All 51 patients had 18F-FDG-avid bone lesions confirmed as
cancer metastases. All 51 patients were eventually confirmed as
having stage IV cancer.
Adequacy of tissue samples for molecular tests
Pathological diagnoses were confirmed by histopathology and
immunohistochemical tests. In addition, adequate tissue sam-
ples made it possible to perform molecular tests. In the 47
biopsies diagnosed with lung cancer, EGFR mutation tests
were examined in 23 cases and the total mutation rate of bone
metastasis was 30.4 % (7/23). ALK mutation tests were per-
formed in 19 cases and the mutation rate of bone metastasis
was 31.6 % (6/19).
Fig. 4 A 62-year-old man with suspected lung carcinoma with multiple
bone metastases. a–c18F-FDG PET/CT imaging (a maximum intensity
projection image. b axial PET image. c axial PET/CT fusion image) shows
uptake (SUVmax 2.1) within a lesion in the right ilium (arrows) highly
suspicious of metastasis. d The CT image shows the biopsy needle
positioned within the right ilium lesion (arrow). e The axial noncontrast CT
image (using bone windows) shows no imaging correlate in the
corresponding region (arrow). Histological examination confirmed a bone
metastasis from small-cell lung cancer of the lung
Fig. 3 A 76-year-old man with suspected lung carcinoma with bone
metastasis. a–c 18F-FDG PET/CT imaging (a maximum intensity
projection image. b axial PET image. c axial PET/CT fusion image) shows
uptake (SUVmax 6.3) in a lesion in the left ilium (arrows) highly suspicious
of metastasis. d The CT image shows the biopsy needle positioned within the
left ilium lesion (arrow). e The axial noncontrast CT image (using bone
windows) shows an osseous abnormality within the corresponding
hypermetabolic region (arrow). Histological examination confirmed a bone
metastasis from poorly differentiated adenocarcinoma of the lung, and exon
21 deletion mutation in EGFR was detected
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Complications
Each biopsy procedure took, on average, approximately 30mi-
nutes. Slight bleeding and pain were encountered in almost all
patients who underwent biopsy, but no serious complications
were noted.
Discussion
Lung cancer has replaced liver cancer as the primary cause of
death among patients with malignancies in China [8]. During
the last three decades, the registered lung cancer mortality rate
has increased by 464.84 %, which is a heavy burden on pa-
tients, health-care professionals, and society [8, 9]. The prog-
nosis of patients with advanced lung cancer is poor, with a 5-
year survival rate of 5 % or less. Recent developments in
cancer genomics and molecular targeted therapy have caused
a major paradigm shift in the management of advanced-stage
lung cancer [10]. Precise staging of patients with lung cancer
now plays a significant role in determining treatment strategy
and prognosis. The accurate definition of tumour stage is a
prerequisite for an individualized, risk-adapted therapy for
lung cancer. Since 18F-FDG PET/CT combines the metabolic
information of PETwith the anatomic information of CT, it is
of significant value in the diagnosis and staging of lung cancer
patients [11]. An additional advantage is that it can be used for
whole-body scanning with the potential to detect local and
distant metastases in a single examination [12].
18F-FDG PET/CT has shown excellent diagnostic accura-
cy in the staging and restaging of a majority of malignant
tumours including NSCLC, lymphoma, breast cancer, and
liver cancer. When patients with an advanced-stage tumour
are accurately staged using18F-FDG PET/CT, inappropriate
surgery is avoided [13]. However, positive 18F-FDG PET/
CT findings for distant disease also require pathological or
radiological confirmation. Histological examination remains
the Bgold standard^ for definitive diagnosis of lung nodules or
lung metastasis. In order to obtain tissue for a histological
diagnosis in patients with suspected lung cancer, CT-guided


























Ilium 34 34 29 31 22 3 6 1 19 6 23 7
Sacrum 4 4 4 4 4 0 0 0
Ischium 4 4 3 4 4 0 0 0
Scapula 2 2 2 2 2 0 0 0
Rib 2 2 2 2 0 0 2 0
Femur 2 2 2 2 2 0 0 0
Clavicle 1 1 1 1 1 0 0 0
Lumbar
vertebra
1 1 1 1 1 0 0 0
Total 48 48 42 45 36 3 8 1 19 6 23 7
Table 1 Patient characteristics, biopsy sites and pathological diagnoses
Variable Value
No. of patients 51
Gender (male/female) 35/16


















Renal cell carcinoma 1
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lung biopsy is commonly used [14]. But this invasive proce-
dure is associated with the risk of complications including
pain, haemoptysis (1% to 10%), pneumothorax (4 % to about
25 %), pneumothorax requiring a chest tube (1 % to about
4 %), air embolism, and atrial fibrillation [14–18]. The elderly
with poor pulmonary function are especially at risk of com-
plications. Besides a biopsy of the primary focus, a biopsy of a
lung metastasis can usually provide a diagnosis in lung cancer
patients. Furthermore, any findings of distant disease can be
confirmed by tissue biopsy to ensure accurate staging of the
disease [19].
According to the 2015 NCCN guidelines regarding
NSCLC, the choice of biopsy should be based on the clinical
suspicion of lung cancer, location of the lesion, and patient
preferences. Patients suspected of having a solitary site of
metastasis should have the disease confirmed in tissue from
that site, if feasible. If it is technically difficult or risky to
biopsy a particular metastatic site, patients who may have
multiple sites of metastatic disease should undergo biopsy of
the primary lung lesion or mediastinal lymph nodes. The latest
guidelines emphasize the importance of biopsying the site of
metastasis as it is preferable to biopsy the pathology that
would confer the highest stage (i.e. it is preferable to biopsy
a suspected metastasis or mediastinal lymph node rather than a
pulmonary lesion [20]).
The optimal puncture site should be selected on the basis of
integrated factors, such as target location, optimal needle path
and shortest skin-to-target distance. First, when selecting the
target location, the most reliably identified focus should be
selected. As mentioned above, selecting metastatic tumour
rather than the primary lung tumour as the target location
may minimize the occurrence of complications. Second, the
optimal needle path is very important, because the biopsy
process needs avoid nearby blood vessels, the spinal nerve
trunk and vital organs. Third, selecting the shortest skin-to-
target distance can simplify the biopsy procedure, save time
and reduce pain. The aim of all these considerations is to
ensure security, feasibility and effectiveness of the procedure.
In general, biopsy of FDG-avid bone metastasis was found to
meet all these factors simultaneously and it should be consid-
ered the best choice for obtaining tumour tissue.
PET imaging is frequently best performed before a diag-
nostic biopsy site is chosen in patients with a high clinical
suspicion of aggressive, advanced-stage tumours. In contrast
to a conventional CT-guided biopsy, 18F-FDG PET/CT guid-
ance allows targeting of the metabolically active mass or the
metabolically active portion of a mass [21]. This novel meth-
od can reduce the false-negative rate and is a relatively safe
and effective way to obtain a pathological diagnosis.
Transoesophageal endobronchial ultrasound-guided
transbronchial needle aspiration (EBUS-TBNA) has a high
sensitivity and specificity for staging mediastinal and hilar
lymph nodes in patients with NSCLC. EBUS-TBNA is of
particular value for the biopsy of PET-positive hilar lymph
nodes [20, 22].
Since lung cancer patients often have bone metastases, it is
important to choose a hypermetabolic bone lesion that is
suspected to be a metastasis from lung cancer as the biopsy
target after the whole-body 18F-FDG PET/CT scan. In the
current study, 51 patients underwent PET/CT-guided percuta-
neous biopsy of 18F-FDG-avid metastatic bone lesions. Bone
metastases from lung cancer were confirmed pathologically in
48 of the 51 patients, and of the other three patients two were
diagnosed as having NHL and one metastatic RCC. Even
though two patients underwent a second biopsy since the path-
ological diagnosis was unclear from the first biopsy, the over-
all sensitivity was 100 % with a 100 % success rate. In all the
patients in this study, the bone biopsy was successful, i.e. the
biopsy needle was positioned correctly in the lesion of inter-
est, and a clinically useful histological result was obtained in
all 51 patients. Compared with biopsy of pulmonary nodules,
bone biopsy avoids hazardous complications such as
haemoptysis and pneumothorax. Despite a small amount of
bleeding and pain, most patients tolerated the procedure well.
Thus, this biopsy method is safe, effective, and feasible as it
minimizes the risks while ensuring that an adequate amount of
tissue is obtained.
An adequate amount of tissue is required for molecular
diagnosis (EGFR or ALK mutation testing), which plays an
important role in the treatment of advanced NSCLC [23].
Conventional methods for obtaining tissue samples such as
CT-guided fine needle aspiration, bronchoalveolar aspirate,
bronchial alveolar lavage or sampling of pleural effusions
provide insufficient material for molecular analysis in a sig-
nificant proportion of patients [23]. Targeted therapy is of
significant value in patients with unresectable lung cancer.
EGFR inhibitors, such as erlotinib and gefitinib, are of signif-
icant benefit in EGFR mutation-positive malignancies, which
are primarily adenocarcinomas [24].
In our study, all lung cancer samples were sufficient to
perform H&E staining or immunohistochemical tests. EGFR
mutation status was determined in 23 of the 51 biopsies of
Table 3 Analysis of the three
PET/CT-guided bone biopsies
with other diagnoses
Diagnosis Cancer history Follow-up of lung nodules
Non-Hodgkin’s lymphoma None Non-Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma None Non-Hodgkin’s lymphoma
Renal cell carcinoma Renal cell carcinoma Metastatic renal cell carcinoma
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bone metastases, and the total mutation rate was 30.4 %
(7/23). ALK mutation status was determined in 19 biopsies,
and the mutation rate was 31.6 % (6/19). Molecular testing of
the biopsies from the remaining lung cancer patients was not
performed due to lack of funds or the subsequent cost of the
targeted treatment. The three other patients had either NHL or
metastatic RCC.
In summary, PET/CT-guided biopsy of bone tissue solved
the problem of insufficient tissue obtained on biopsy. Our
samples from PET/CT-guided biopsy were ample for our
needs and enabled us to do more studies with less tissue, i.e.
the adequate amount of tissue obtained guaranteed a success-
ful molecular test result.
Conclusion
This study demonstrated that 18F-FDG PET/CT guidance of-
fers the opportunity to precisely target morphologically inde-
terminate bone lesions for tissue sampling. In lung cancer
patients with suspected bone metastases, percutaneous biopsy
of 18F-FDG-avid metastatic bone lesions is feasible and effec-
tive, and can be performed safely with few complications. The
use of this biopsy method allows staging and pathological
diagnosis. Adequate amounts of tissue can guarantee success-
ful molecular testing, the result of which can be used for indi-
vidualized treatment and targeted therapy. Thus, percutaneous
biopsy of 18F-FDG-avid metastatic bone lesions plays an im-
portant role in the diagnosis and staging of lung cancer pa-
tients with suspected bone metastasis.
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